No ratings

Howdy everyone. How was your Wednesday? For the market it was.... complicated.

Did you ever play the board game called Mouse Trap when you were a kid? You know the one, where you try to move your mouse around the board before a chain reaction of events springs the trap and catches your mouse? It starts with a shoe that kicks a bucket, spilling a metal ball down the stairs and into a gutter, where it lands in a hand that places it in a bathtub... well, you get the idea. Everything that happens on the game board was set into motion by something else.

That's kind of how today was - everything that happened was in response to an initial action, and that action was Wednesday morning's ADP payroll growth report. Long story made short, economists were expecting to see job growth of 180,000 payrolls, but we saw a whopping 298,000 new jobs created in February.

No ratings

Howdy folks - how was your Tuesday? Not a great one for the market, obviously, and a downright miserable one for Snap (SNAP)... as we suspected would be the case in yesterday's newsletter. Well, we can 't do anything about Snap, but we will point out that although we've mostly been pessimists of late, it's not like the broad market has pushed past the point of no return yet. It's getting close though.

We'll look at it in a moment. The first thing we want to cross of our checklist today is a trio of news reports from our list of Featured Stocks. Two of the three updates are from gold mining stocks, so if you love resource plays, you'll definitely want to keep reading.

Our first look at Nexus Gold (CVE:NXS, NXXGF) was way back on November 23rd. The story has progressed very quickly in the meantime, with the latest chapter being logged today. All the recent sampling work being done at the Niangouela gold concession in Burkina Faso, Africa? Yeah, well, it's been completed, and the results look as fantastic as we expected them to be.

No ratings

Hello friends and fellow traders, and welcome back from the weekend. We hope you had a good one, although any of you who were hoping the bulls would take charge again on Monday are now probably wishing it had been a three-day weekend.

All the same, it's not like the market stumbled past the point of no return - there's still a glimmer of hope. It'll take a lot of work from the bulls to prevent this weakness from turning into a major setback, but if there's one thing we've learned since early November, it's to assume nothing.

Anyway, that's not what we wanted to discuss today. Our only focal point for this edition is chiming in on a matter we're sure most of you are familiar with... the recent IPO of Snapchat's parent company, Snap Inc. (SNAP).

No ratings

Do you ever get the feeling the federal government is uncomfortably trapped between providing enough protection from terrorism threats and not wanting to threaten your basic, reasonable freedoms?

Realistically speaking, we'd have to answer 'yes' to our question. But, we'll also express our sympathy for the predicament. Seeing a nation's people's basic rights under attack or seeing them being consistently inconvenienced is just as bad as knowing they're at risk at any given moment.

There's the rub.... the trade-off.

No ratings

It seems difficult (almost impossible) to believe, but the world's not seen a major evolution in the way we treat diabetes since the discovery and subsequent use of insulin nearly 100 years ago. Oh, we've seen delivery methods improve -- like inhalable insulin -- and glucose monitoring technology is practically automated anyhow. When you get right down to brass tacks though, where we are now is where we were when Frederick Banting injected a diabetic with insulin at the University of Toronto.... way back on January 11th of 1922.

An up-and-coming biotech company called Cell MedX Corp. (CMXC) could be about to break the world out of that R&D rut, however.

The science is called electromedicine, and it's exactly what it sounds like. That is, the application of mild electrical currents to different parts of the body to induce better cellular health, including better glucose processing.